Efficacy of nobiletin in improving hypercholesterolemia and nonalcoholic fatty liver disease in high-cholesterol diet-fed mice

키워드

참고문헌 (46)

1. Yasutake K, "Nutritional investigation of non-obese patients with non-alcoholic fatty liver disease : the significance of dietary cholesterol", Scand J Gastroenterol, 44, pp.471~477 (2009)
2. Musso G, "Dietary habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic steatohepatitis", Hepatology, 37, pp.909~916 (2003)
3. Min HK, "Increased hepatic synthesis and dysregulation of cholesterol metabolism is associated with the severity of nonalcoholic fatty liver disease", Cell Metab, 15, pp.665~674 (2012)
4. Matsuzawa N, "Lipid-induced oxidative stress causes steatohepatitis in mice fed an atherogenic diet", Hepatology, 46, pp.1392~1403 (2007)
5. Tu LN, "Metabolomic characteristics of cholesterol-induced non-obese nonalcoholic fatty liver disease in mice", Sci Rep, 7, pp.6120~ (2017)
6. Targher G, "Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients", Diabetes, 54, pp.3541~3546 (2005)
7. Hamaguchi M, "Nonalcoholic fatty liver disease is a novel predictor of cardiovascular disease", World J Gastroenterol, 13, pp.1579~1584 (2007)
8. Huang H, "The multifunctional effects of nobiletin and its metabolites in vivo and in vitro", Evid Based Complement Alternat Med, 2016, pp.2918796~ (2016)
9. Yuk T, "Nobiletin inhibits hepatic lipogenesis via activation of AMP-activated protein kinase", Evid Based Complement Alternat Med, 2018, pp.7420265~ (2018)
10. Cirillo P, "Nobiletin inhibits oxidized-LDL mediated expression of tissue factor in human endothelial cells through inhibition of NF-κB", Biochem Pharmacol, 128, pp.26~33 (2017)
11. Mulvihill EE, "Nobiletin attenuates VLDL overproduction, dyslipidemia, and atherosclerosis in mice with diet-induced insulin resistance", Diabetes, 60, pp.1446~1457 (2011)
12. Burke AC, "Intervention with citrus flavonoids reverses obesity and improves metabolic syndrome and atherosclerosis in obese Ldlr−", − mice, 2018, pp.59, 1714~1728
13. Kim YJ, "Long-term dietary supplementation with low-dose nobiletin ameliorates hepatic steatosis, insulin resistance, and inflammation without altering fat mass in diet-induced obesity", Mol Nutr Food Res, 61, pp.1600889~ (2017)
14. Folch J, "A simple method for the isolation and purification of total lipides from animal tissues", J Biol Chem, 226, pp.497~509 (1957)
15. Shapiro DJ, "Micro assay for 3-hydroxy-3-methylglutaryl-CoA reductase in rat liver and in L-cell fibroblasts", Biochim Biophys Acta, 370, pp.369~377 (1974)
16. Erickson SK, "Rat liver acyl-coenzyme A : cholesterol acyltransferase : its regulation in vivo and some of its properties in vitro", J Lipid Res, 21, pp.930~941 (1980)
17. Nepokroeff CM, "Fatty-acid synthase from rat liver", Methods Enzymol, 35, pp.37~44 (1975)
18. Markwell MA, "The subcellular distribution of carnitine acyltransferases in mammalian liver and kidney. A new peroxisomal enzyme", J Biol Chem, 248, pp.3426~3432 (1973)
19. Lazarow PB, "Assay of peroxisomal β-oxidation of fatty acids", Methods Enzymol, 72, pp.315~319 (1981)
20. Bradford MM, "A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding", Anal Biochem, 72, pp.248~254 (1976)
21. Mackness MI, "Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein", FEBS Lett, 286, pp.152~154 (1991)
22. Paigen B, "Ath-1, a gene determining atherosclerosis susceptibility and high density lipoprotein levels in mice", Proc Natl Acad Sci U S A, 84, pp.3763~3767 (1987)
23. Jawień J, "Mouse models of experimental atherosclerosis", J Physiol Pharmacol, 55, pp.503~517 (2004)
24. Whitman SC, "Nobiletin, a citrus flavonoid isolated from tangerines, selectively inhibits class A scavenger receptor-mediated metabolism of acetylated LDL by mouse macrophages", Atherosclerosis, 178, pp.25~32 (2005)
25. Nohara K, "Coordinate regulation of cholesterol and bile acid metabolism by the clock modifier nobiletin in metabolically challenged old mice", Int J Mol Sci, 20, pp.4281~ (2019)
26. Morrow NM, "The citrus flavonoid nobiletin confers protection from metabolic dysregulation in high-fat-fed mice independent of AMPK", J Lipid Res, 61, pp.387~402 (2020)
27. Owens AP, "Monocyte tissue factor-dependent activation of coagulation in hypercholesterolemic mice and monkeys is inhibited by simvastatin", J Clin Invest, 122, pp.558~568 (2012)
28. Navab M, "The oxidation hypothesis of atherogenesis : the role of oxidized phospholipids and HDL", J Lipid Res, 45, pp.993~1007 (2004)
29. Meisinger C, "Plasma oxidized low-density lipoprotein, a strong predictor for acute coronary heart disease events in apparently healthy, middle-aged men from the general population", Circulation, 112, pp.651~657 (2005)
30. Rifai N, "Is C-reactive protein specific for vascular disease in women?", Ann Intern Med, 136, pp.529~533 (2002)
31. Ridker PM, "Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events", N Engl J Med, 347, pp.1557~1565 (2002)
32. Zhang D, "The effect of interleukin-1 on C-reactive protein expression in Hep3B cells is exerted at the transcriptional level", Biochem J, 310, pp.143~148 (1995)
33. Yudkin JS, "Inflammation, obesity, stress and coronary heart disease : is interleukin-6 the link?", Atherosclerosis, 148, pp.209~214 (2000)
34. Weinhold B, "Interleukin-6-dependent and-independent regulation of the human C-reactive protein gene", Biochem J, 327, pp.425~429 (1997)
35. Dawson S, "The status of PAI-1 as a risk factor for arterial and thrombotic disease : a review", Atherosclerosis, 95, pp.105~117 (1992)
36. Hui X, "Adiponectin and cardiovascular health : an update", Br J Pharmacol, 165, pp.574~590 (2012)
37. Baluta MM, "PAI-1 inhibition-another therapeutic option for cardiovascular protection", Maedica(Bucur), 10, pp.147~152 (2015)
38. Ng CJ, "Paraoxonase-2 deficiency aggravates atherosclerosis in mice despite lower apolipoprotein-B-containing lipoproteins : anti-atherogenic role for paraoxonase-2", J Biol Chem, 281, pp.29491~29500 (2006)
39. Litvinov D, "Antioxidant and anti-inflammatory role of paraoxonase 1 : implication in arteriosclerosis diseases", N Am J Med Sci, 4, pp.523~532 (2012)
40. Trapani L, "Regulation and deregulation of cholesterol homeostasis : the liver as a metabolic"power station"", World J Hepatol, 4, pp.184~190 (2012)
41. Parini P, "ACAT2 is localized to hepatocytes and is the major cholesterol-esterifying enzyme in human liver", Circulation, 110, pp.2017~2023 (2004)
42. Zhang J, "Tissue-specific knockouts of ACAT2 reveal that intestinal depletion is sufficient to prevent diet-induced cholesterol accumulation in the liver and blood", J Lipid Res, 53, pp.1144~1152 (2012)
43. Meiner VL, "Disruption of the acyl-CoA : cholesterol acyltransferase gene in mice : evidence suggesting multiple cholesterol esterification enzymes in mammals", Proc Natl Acad Sci U S A, 93, pp.14041~14046 (1996)
44. Sharpe LJ, "Controlling cholesterol synthesis beyond 3-hydroxy-3-methylglutaryl-CoA reductase(HMGCR)", J Biol Chem, 288, pp.18707~18715 (2013)
45. Arguello G, "Recent insights on the role of cholesterol in non-alcoholic fatty liver disease", Biochim Biophys Acta, 1852, pp.1765~1778 (2015)
46. Alger HM, "Inhibition of acyl-coenzyme A : cholesterol acyltransferase 2(ACAT2)prevents dietary cholesterol-associated steatosis by enhancing hepatic triglyceride mobilization", J Biol Chem, 285, pp.14267~14274 (2010)

관련 논문AI추천